Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The country's government aims to promote the commercialization of publicly funded research and to boost private investment into its nascent biotech sector.
Budding bioentrepreneurs need an information-gathering strategy that balances time and budgetary constraints when deciding whether to sift through the glut of free information on biotech or to opt for subscription services offering higher quality, more insightful analysis.
Heavy workload, high staff turnover and poor marketing practices have hampered transfer of technologies from the National Institutes of Health to industry.
Howard Bremer, whose career has tracked with and influenced the development of university technology transfer initiatives, reflects on his path and where it has led both him and the evolving debate over use of federally funded inventions.
Many biotech companies are founded by scientists. But there is certainly a path, somewhat less trodden but nonetheless viable, for the inspired entrepreneur who may not be a brilliant researcher.
Regional biotech industry groups throughout Germany are cooperating with each other to enhance the international competitiveness of the country's biotech sector.
As a UK-Texas collaboration gets ready to launch its first biotech firm, many regional industry organizations see the future of startups in such programs.
As big pharmas fall over each other to proclaim themselves the 'partner of choice' for biotechs, there are still some lessons the younger sibling can learn.